This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB01583/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01583/identifier/drugbank/
n18http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n14http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB01583/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n7http://www.rxlist.com/cgi/generic/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01583/identifier/pharmgkb/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01583/identifier/pubchem-compound/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01583
rdf:type
n3:Drug
n3:description
Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion. It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues. Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage. In fact, administration of T3 may result in supratherapeutic levels of T3.
n3:dosage
n21:271B5837-363D-11E5-9242-09173F13E4C5 n21:271B5838-363D-11E5-9242-09173F13E4C5 n21:271B5839-363D-11E5-9242-09173F13E4C5 n21:271B583A-363D-11E5-9242-09173F13E4C5 n21:271B583B-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Cobb WE, Jackson IM: Drug therapy reviews: management of hypothyroidism. Am J Hosp Pharm. 1978 Jan;35(1):51-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/341699
n3:group
approved
n3:indication
May be used to treat primary, secondary or tertiary hypothyroidism. May also be used to suppress thyroid stimulating hormone (TSH) secretion in patients with simple (nontoxic) goiter, subacute or chronic lymphocytic thyroiditis multinodular goiter, and in the management of thyroid cancer. May be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism. May also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy.
owl:sameAs
n14:DB01583 n22:DB01583
dcterms:title
Liotrix
adms:identifier
n9:PA164748036 n11:DB01583 n12:64467 n15:71371 n16:46506203
n3:mechanismOfAction
The hormones, T<sub>4</sub> and T<sub>3</sub>, are tyrosine-based hormones produced by the thyroid gland. Iodine is an important component in their synthesis. The major secreted form of thyroid hormone is T4. T4 is converted T3, the more active thyroid hormone, by deiodinases in peripheral tissues. T3 acts in the body to increase basal metabolic rate, alter protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline). Thyroid hormones are essential for proper development and differentiation of all cells of the human body. T<sub>4</sub> and T<sub>3</sub> regulate protein, fat and carbohydrate metabolism to varying extents. The most pronounced effect of the hormones is in altering how human cells use energetic compounds. The thyroid hormone derivatives bind to the thyroid hormone receptors initially to initiate their downstream effects.
n3:packager
n18:271B5831-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Thyroid hormones are primarily eliminated by the kidneys.
n3:synonym
Levothyroxine sodium - liothyronine sodium mixt Thyrolar
n3:toxicity
Hypermetabolic state indistinguishable from thyrotoxicosis of endogenous origin. Symptoms of thyrotoxicosis include weight loss, increased appetite, palpitations, nervousness, diarrhea, abdominal cramps, sweating, tachycardia, increased pulse and blood pressure, cardiac arrhythmias, tremors, insomnia, heat intolerance, fever, and menstrual irregularities.
n19:hasAHFSCode
n20:68-36-04
n3:foodInteraction
Absorption increased in fasting state and decreased in malabsorption states. Oral administration with infant soybean formula, soybean flour, cotton seed meal, walnuts, foods containing large amounts of fiber, ferrous sulfate, and antacids may decrease drug absorption. Consistent administration in relation to meals is recommended. Iron and calcium may interfere with absorption. Space doses at least one hour before or after iron or calcium intake. Take 30-60 minutes before breakfast.
foaf:page
n7:liot.htm n17:liotrix.html
n3:IUPAC-Name
n5:271B583D-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5843-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5842-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B583F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5840-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5841-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B583C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n5:271B5849-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B584A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5844-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5845-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5847-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5846-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5848-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
8065-29-0
n3:category
n3:containedIn
n4:271B5832-363D-11E5-9242-09173F13E4C5 n4:271B5833-363D-11E5-9242-09173F13E4C5 n4:271B5836-363D-11E5-9242-09173F13E4C5 n4:271B5834-363D-11E5-9242-09173F13E4C5 n4:271B5835-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B584F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5851-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5852-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B584E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B584D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5850-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B583E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B584B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B584C-363D-11E5-9242-09173F13E4C5